BioSpace News Archive

Significant 12-month overall survival benefit in the CPB7 population and 2 patients are still under treatment for more than 3.5 years Namodenoson is headed into a global pivotal Phase III study

Dr. Toralf Haag appointed to Supervisory Board and a member of the Audit Committee

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has agreed to acquire TransChart LLC, an Ohio-based provider of electronic health record software supporting the needs of US transplant centers. The transaction is expected to close in Ja

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today announced top-line results from its 755-102-HV Phase 1 clinical trial (“Study 102").

RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPID) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that the Company’s senior management will participate in two virtual investor conferences in January

Galecto, Inc., (NASDAQ: GLTO) a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of Dr. Anne Prener to its Board of Directors.

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will present at two upcoming investor conferences:

Immune Regulation, LTD, announced today that the company will give a corporate overview at the virtual 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 7:30 a.m. EST.

- Additional data from ongoing gavo-cel Phase 1/2 trial to be presented in 1H21 - Identification of gavo-cel recommended Phase 2 dose and initiation of Phase 2 study expected in 2021 - Initial data from ongoing TC-110 Phase 1/2 trial anticipated in 2021 - IND for third program on track to file in 2021 - Preclinical data from allogeneic TRuC-T cell program targeting mesothelin anticipated in 2021 - Preclinical data presentations from new autologous TRuC-T cell programs anticipated in 2021

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and develop a vaccine to fight COVID-19, today announced that it will present at the 2021 CTIC 5th Healthcare Investment Summit being held on January 9-10, the H.C. Wainwright BioConnect Conference